Price criteria in Indian Glivec patent case 'unprecedented', Novartis says
This article was originally published in Scrip
Executive Summary
Novartis said that it "takes issue" with the India Intellectual Property Appellate Board's (IPAB) contention that its drug Glivec (imatinib mesylate) is "too unaffordable to the poor cancer patients in India". Citing Section 3 (b) of the Indian patent law, IPAB said that a patent would "create a havoc to the lives of poor" cancer patients, and "have disastrous effect on the society as well."